Translocation of Nucleoside Analogs Across the Plasma Membrane in Hematologic Malignancies

REFERENCES

• Robak , T. , Lech-Maranda , E. , Korycka , A. and Robak , E. 2006 . Purine nucleoside analogs as immunosuppressive ans antineoplastic agents: mechanism of action and clinical activity . Curr. Med. Chem. , 13 : 3165 – 3189 .
   PubMed Web of Science ®Google Scholar
• Pettit , A. R. 2003 . Mechanism of action of purine analogues in chronic lymphocytic leukemia . Br. J. Haematol. , 121 : 692 – 702 .
   PubMedGoogle Scholar
• Korycka , A. , Lech-Maranda , E. and Robak , T. 2008 . Novel purine nucleoside analogues for hematological malignancies . Recent Pat. Anticancer. Drug Discov. , 3 : 123 – 136 .
   PubMed Web of Science ®Google Scholar
• Tsuzuki , M. , Handa , K. , Yamamoto , K. , Hasegawa , A. , Yamamoto , Y. , Watanabe , M. , Mizuta , S. , Maruyama , F. , Okamoto , M. , Emi , N. and Ezaki , K. 2008 . Chronic myeloid leukemia following chemotherapy with 5′-deoxy-5-fluorouridine for gastric cancer . Intern. Med. , 47 ( 19 ) : 1739 – 1741 .
   PubMedGoogle Scholar
• Wang , W. S. , Tzeng , C. H. , Chiou , T. J. , Liu , J. H. , Hsieh , R. K. , Yen , C. C. and Chen , P. M. 1997 . High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-Hodgkin's lymphoma . Jpn J. Clin. Oncol. , 27 ( 3 ) : 154 – 157 .
   PubMedGoogle Scholar
• Burnett , A. , Wetzler , M. and Löwenberg , B. 2011 . Therapeutic advances in acute myeloid leukemia . J. Clin. Oncol. , 29 ( 5 ) : 487 – 494 .
   PubMed Web of Science ®Google Scholar
• Jabbour , E. , Cortes , J. E. , Giles , F. J. , O’Brien , S. and Kantarjian , H. M. 2007 . Current and emerging treatment options in chronic myeloid leukemia . Cancer , 109 ( 11 ) : 2171 – 2181 .
   PubMed Web of Science ®Google Scholar
• Shah , M. and Agarwal , B. 2008 . Recent advances in management of acute myeloid leukemia (AML) . Indian J. Pediatr. , 75 ( 8 ) : 831 – 837 .
   PubMedGoogle Scholar
• Wong , A. , Soo , R. A. , Yong , W. P. and Innocenti , F. 2009 . Clinical pharmacology and pharmacogenetics of gemcitabine . Drug Metab. Rev. , 41 ( 2 ) : 77 – 88 .
   PubMed Web of Science ®Google Scholar
• Robak , T. , Korycka , A. , Lech-Maranda , E. and Robak , P. 2009 . Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases . Molecules , 14 ( 3 ) : 1183 – 1226 .
   PubMed Web of Science ®Google Scholar
• Bellezza , I. , Tucci , A. and Minelli , A. 2008 . 2-Chloroadenosine and human prostate cancer cells . Anticancer Agents Med. Chem. , 8 ( 7 ) : 783 – 789 .
   PubMedGoogle Scholar
• Hentosh , P. and Peffley , D. M. 2010 . The cladribine conundrum: deciphering the drug's mechanism of action . Expert Opin. Drug Metab. Toxicol. , 6 ( 1 ) : 75 – 81 .
   PubMed Web of Science ®Google Scholar
• Robak , T. 2006 . Current treatment options in hairy cell leukemia and hairy cell leukemia variant . Cancer Treat. Rev. , 32 ( 5 ) : 365 – 376 .
   PubMed Web of Science ®Google Scholar
• Sauter , C. , Lamanna , N. and Weiss , M. A. 2008 . Pentostatin in chronic lymphocytic leukemia . Expert Opin. Drug Metab. Toxicol. , 4 ( 9 ) : 1217 – 1222 .
   PubMed Web of Science ®Google Scholar
• Parker , W. B. , Secrist , J. A. III and Waud , W. R. 2004 . Purine nucleoside antimetabolites in development for the treatment of cancer . Curr. Opin. Investig. Drugs , 5 ( 6 ) : 592 – 596 .
   PubMedGoogle Scholar
• Faderl , S. , Gandhi , V. , Keating , M. J. , Jeha , S. , Plunkett , W. and Kantarjian , H. M. 2005 . The role of clofarabine in hematologic and solid malignancies—development of a next-generation nucleoside analog . Cancer , 103 ( 10 ) : 1985 – 1995 .
   PubMedGoogle Scholar
• Pui , C. H. , Jeha , S. and Kirkpatrick , P. 2006 . Clofarabine . Nat. Rev. Drug Discov. , 4 : 369 – 370 .
   Google Scholar
• Balakrishnan , K. , Nimmanapalli , R. , Ravandi , F. , Keating , M. J. and Gandhi , V. 2006 . Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells . Blood , 108 : 2392 – 2398 .
   PubMed Web of Science ®Google Scholar
• Korycka , A. , Błoński , J. Z. and Robak , T. 2007 . Forodesine (BCX-1777, Immucillin H)—a new purine nucleoside analogue: mechanism of action and potential clinical application . Mini. Rev. Med. Chem. , 7 : 976 – 983 .
   PubMed Web of Science ®Google Scholar
• Robak , T. 2011 . New nucleoside analogs for patients with hematological malignancies . Expert Opin. Investig. Drugs , 20 ( 3 ) : 343 – 359 .
   PubMed Web of Science ®Google Scholar
• Alonso , R. , López-Guerra , M. , Upshaw , R. , Bantia , S. , Smal , C. , Bontemps , F. , Manz , C. , Mehrling , T. , Villamor , N. , Campo , E. , Montserrat , E. and Colomer , D. 2009 . Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM . Blood , 114 ( 8 ) : 1563 – 1575 .
   PubMedGoogle Scholar
• Cohen , M. H. , Johnson , J. R. , Justice , R. and Pazdur , R. 2008 . FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma . Oncologist , 13 : 709 – 714 .
   PubMed Web of Science ®Google Scholar
• Garcia-Manero , G. 2008 . Demethylating agents in myeloid malignancies . Curr. Opin. Oncol. , 20 ( 6 ) : 705 – 710 .
   PubMedGoogle Scholar
• Hollenbach , P. W. , Nguyen , A. N. , Brady , H. , Williams , M. , Ning , Y. , Richard , N. , Krushel , L. , Aukerman , S. L. , Heise , C. and MacBeth , K. J. 2010 . A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines . PLoS One , 5 ( 2 ) : E9001
   PubMed Web of Science ®Google Scholar
• Garcia-Manero , G. and Fenaux , P. 2011 . Hypomethylating agents and other novel strategies in myelodysplastic syndromes . J. Clin. Oncol. , 29 ( 5 ) : 516 – 523 .
   PubMed Web of Science ®Google Scholar
• Ritzel , M. W. , Yao , S. Y. , Huang , M. Y. , Elliott , J. F. , Cass , C. E. and Young , J. D. 1997 . Molecular cloning and functional expression of cDNAs encoding a human Na+-nucleoside cotransporter (hCNT1) . Am. J. Physiol. , 272 ( 2 Pt. 1 ) : C707 – C714 .
   PubMedGoogle Scholar
• Ritzel , M. W. , Yao , S. Y. , Ng , A. M. , Mackey , J. R. , Cass , C. E. and Young , J. D. 1998 . Molecular cloning, functional expression and chromosomal localization of a cDNA encoding a human Na+/nucleoside cotransporter (hCNT2) selective for purine nucleosides and uridine . Mol. Membr. Biol. , 15 ( 4 ) : 203 – 211 .
   PubMed Web of Science ®Google Scholar
• Wang , J. , Su , S. F. , Dresser , M. J. , Schaner , M. E. , Washington , C. B. and Giacomini , K. M. 1997 . Na(+)-dependent purine nucleoside transporter from human kidney: cloning and functional characterization . Am. J. Physiol. , 273 ( 6 Pt. 2 ) : F1058 – F1065 .
   PubMedGoogle Scholar
• Smith , K. M. , Ng , A. M. , Yao , S. Y. , Labedz , K. A. , Knaus , E. E. , Wiebe , L. I. , Cass , C. E. , Baldwin , S. A. , Chen , X. Z. , Karpinski , E. and Young , J. D. 2004 . Electrophysiological characterization of a recombinant human Na+-coupled nucleoside transporter (hCNT1) produced in Xenopus oocytes . J. Physiol. , 558 ( Pt. 3 ) : 807 – 823 .
   PubMed Web of Science ®Google Scholar
• Mackey , J. R. , Yao , S. Y. , Smith , K. M. , Karpinski , E. , Baldwin , S. A. , Cass , C. E. and Young , J. D. 1999 . Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters . J. Natl. Cancer Inst. , 91 ( 21 ) : 1876 – 1881 .
   PubMedGoogle Scholar
• Lang , T. T. , Young , J. D. and Cass , C. E. 2004 . Interactions of nucleoside analogs, caffeine, and nicotine with human concentrative nucleoside transporters 1 and 2 stably produced in a transport-defective human cell line . Mol. Pharmacol. , 65 ( 4 ) : 925 – 933 .
   PubMedGoogle Scholar
• Fotoohi , A. K. , Lindqvist , M. , Peterson , C. and Albertioni , F. 2006 . Involvement of the concentrative nucleoside transporter 3 and equilibrative nucleoside transporter 2 in the resistance of T-lymphoblastic cell lines to thiopurines . Biochem. Biophys. Res. Commun. , 343 ( 1 ) : 208 – 215 .
   PubMed Web of Science ®Google Scholar
• Fernandez-Veledo , S. , Huber-Ruano , I. , Aymerich , I. , Duflot , S. , Casado , F. J. and Pastor-Anglada , M. 2006 . Bile acids alter the subcellular localization of CNT2 (concentrative nucleoside cotransporter) and increase CNT2-related transport activity in liver parenchymal cells . Biochem. J. , 395 ( 2 ) : 337 – 344 .
   PubMedGoogle Scholar
• Errasti Murrugarren , E. , Pastor Anglada , M. and Casado , F. J. 2007 . Role of CNT3 in the transepithelial flux of nucleosides and nucleoside-derived drugs . J. Physiol. , 582 ( Pt. 3 ) : 1249 – 1260 .
   PubMedGoogle Scholar
• Ritzel , M. W. , Ng , A. M. , Yao , S. Y. , Graham , K. , Loewen , S. K. , Smith , K. M. , Ritzel , R. G. , Mowles , D. A. , Carpenter , P. , Chen , X. Z. , Karpinski , E. , Hyde , R. J. , Baldwin , S. A. , Cass , C. E. and Young , J. D. 2001 . Molecular identification and characterization of novel human and mouse concentrative Na+-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib) . J. Biol. Chem. , 276 ( 4 ) : 2914 – 2927 .
   PubMed Web of Science ®Google Scholar
• Damaraju , V. L. , Damaraju , S. , Young , J. D. , Baldwin , S. A. , Mackey , J. , Sawyer , M. B. and Cass , C. E. 2003 . Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy . Oncogene , 22 ( 47 ) : 7524 – 7536 .
   PubMed Web of Science ®Google Scholar
• Pastor-Anglada , M. , Molina-Arcas , M. , Casado , F. J. , Bellosillo , B. , Colomer , D. and Gil , J. 2004 . Nucleoside transporters in chronic lymphocytic leukaemia . Leukemia , 18 ( 3 ) : 385 – 393 .
   PubMed Web of Science ®Google Scholar
• Osses , N. , Pearson , J. D. , Yudilevich , D. L. and Jarvis , S. M. 1996 . Hypoxanthine enters human vascular endothelial cells (ECV 304) via the nitrobenzylthioinosine-insensitive equilibrative nucleoside transporter . Biochem. J. , 317 : 843 – 848 .
   PubMed Web of Science ®Google Scholar
• Yao , S. Y. , Ng , A. M. , Vickers , M. F. , Sundaram , M. , Cass , C. E. , Baldwin , S. A. and Young , J. D. 2002 . Functional and molecular characterization of nucleobase transport by recombinant human and rat equilibrative nucleoside transporters 1 and 2. Chimeric constructs reveal a role for the ENT2 helix 5–6 region in nucleobase translocation . J. Biol. Chem. , 277 ( 28 ) : 24938 – 24948 .
   PubMed Web of Science ®Google Scholar
• King , K. M. , Damaraju , V. L. , Vickers , M. F. , Yao , S. Y. , Lang , T. , Tackaberry , T. E. , Mowles , D. A. , Ng , A. M. , Young , J. D. and Cass , C. E. 2006 . A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems . Mol. Pharmacol. , 69 ( 1 ) : 346 – 353 .
   PubMed Web of Science ®Google Scholar
• Weiss , J. , Theile , D. , Ketabi-Kiyanvash , N. , Lindenmaier , H. and Haefeli , W. 2007 . Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors . Drug Metab. Dispos. , 35 ( 3 ) : 340 – 344 .
   PubMed Web of Science ®Google Scholar
• Servais , A. , Lechat , P. , Zahr , N. , Urien , S. , Aymard , G. , Jaudon , M. C. , Deray , G. and Isnard Bagnis , C. 2005 . Tubular transporters OAT1 and MRP2 and clearance of adefovir . Nephrol. Ther. , 1 ( 5 ) : 296 – 300 .
   PubMedGoogle Scholar
• Cundy , K. C. 1999 . Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir . Clin. Pharmacokinet. , 36 ( 2 ) : 127 – 143 .
   PubMed Web of Science ®Google Scholar
• de Wolf , C. , Jansen , R. , Yamaguchi , H. , de Haas , M. , van de Wetering , K. , Wijnholds , J. , Beijnen , J. and Borst , P. 2008 . Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides . Mol. Cancer Ther. , 7 ( 9 ) : 3092 – 3102 .
   PubMedGoogle Scholar
• Hopper-Borge , E. , Xu , X. , Shen , T. , Shi , Z. , Chen , Z. S. and Kruh , G. D. 2009 . Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B . Cancer Res. , 69 ( 1 ) : 178 – 184 .
   PubMed Web of Science ®Google Scholar
• Guo , Y. , Kotova , E. , Chen , Z. S. , Lee , K. , Hopper-Borge , E. , Belinsky , M. G. and Kruh , G. D. 2003 . MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2′,3′-dideoxycytidine and 9′-(2′-phosphonylmethoxyethyl)adenine . J. Biol. Chem. , 278 ( 32 ) : 29509 – 29514 .
   PubMed Web of Science ®Google Scholar
• Molina-Arcas , M. , Bellosillo , B. , Casado , F. J. , Montserrat , E. , Gil , J. , Colomer , D. and Pastor-Anglada , M. 2003 . Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia . Blood , 101 ( 6 ) : 2328 – 2334 .
   PubMed Web of Science ®Google Scholar
• Ritzel , M. W. , Ng , A. M. , Yao , S. Y. , Graham , K. , Loewen , S. K. , Smith , K. M. , Hyde , R. J. , Karpinski , E. , Cass , C. E. , Baldwin , S. A. and Young , J. D. 2001 . Recent molecular advances in studies of the concentrative Na+-dependent nucleoside transporter (CNT) family: identification and characterization of novel human and mouse proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib) . Mol. Membr. Biol. , 18 ( 1 ) : 65 – 72 .
   PubMed Web of Science ®Google Scholar
• Robey , R. W. , To , K. K. , Polgar , O. , Dohse , M. , Fetsch , P. , Dean , M. and Bates , S. E. 2009 . ABCG2: a perspective . Adv. Drug Deliv. Rev. , 61 ( 1 ) : 3 – 13 .
   PubMed Web of Science ®Google Scholar
• Damiani , D. , Tiribelli , M. , Michelutti , A. , Geromin , A. , Cavallin , M. , Fabbro , D. , Pianta , A. , Malagola , M. , Damante , G. , Russo , D. and Fanin , R. 2010 . Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients . Leuk. Res. , 34 ( 7 ) : 942 – 945 .
   PubMedGoogle Scholar
• Dighiero , G. and Hamblin , T. J. 2008 . Chronic lymphocytic leukaemia . Lancet , 371 : 1017 – 1029 .
   PubMed Web of Science ®Google Scholar
• Zenz , T. , Mertens , D. , Küppers , R. , Döhner , H. and Stilgenbauer , S. 2010 . From pathogenesis to treatment of chronic lymphocytic leukaemia . Nat. Rev. Cancer , 10 ( 1 ) : 37 – 50 .
   PubMed Web of Science ®Google Scholar
• Chiorazzi , N. , Rai , K. R. and Ferrarini , M. 2005 . Chronic lymphocytic leukemia . N. Engl. J. Med. , 352 ( 8 ) : 804 – 815 .
   PubMed Web of Science ®Google Scholar
• Chiorazzi , N. and Ferrarini , M. 2011 . Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities . Blood , 117 ( 10 ) : 1781 – 1791 .
   PubMedGoogle Scholar
• Caligaris-Cappio , F. and Ghia , P. 2008 . Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? . J. Clin. Oncol. , 26 ( 27 ) : 4497 – 4503 .
   PubMed Web of Science ®Google Scholar
• Munk Pedersen , I. and Reed , J. 2004 . Microenvironmental interactions and survival of CLL B-cells . Leuk. Lymphoma , 45 ( 1 ) : 2365 – 2372 .
   PubMedGoogle Scholar
• Galmarini , C. M. , Mackey , J. R. and Dumontet , C. 2001 . Nucleoside analogues: mechanisms of drug resistance and reversal strategies . Leukemia , 15 ( 6 ) : 875 – 890 .
   PubMed Web of Science ®Google Scholar
• Galmarini , C. M. , Mackey , J. R. and Dumontet , C. 2002 . Nucleoside analogues and nucleobases in cancer treatment . Lancet Oncol. , 3 ( 7 ) : 415 – 424 .
   PubMed Web of Science ®Google Scholar
• Pastor-Anglada , M. , Cano-Soldado , P. , Molina-Arcas , M. , Lostao , M. P. , Larrayoz , I. , Martinez-Picado , J. and Casado , F. J. 2005 . Cell entry and export of nucleoside analogues . Virus Res. , 107 ( 2 ) : 151 – 164 .
   PubMed Web of Science ®Google Scholar
• O’Brien , S. , Kantarjian , H. and Keating , M. J. 1996 . Purine analogs in chronic lymphocytic leukemia and Waldenstrom's macroglobulinaemia . Ann. Oncol. , 7 ( 6 ) : S27 – S33 .
   PubMedGoogle Scholar
• Cheson , B. 1998 . The purine analogs—a therapeutic beauty contest . J. Clin. Oncol. , 10 : 352 – 355 .
   Google Scholar
• Rai , K. R. , Peterson , B. L. , Appelbaum , F. R. , Kolitz , J. , Elias , L. , Shepherd , L. , Hines , J. , Threatte , G. A. , Larson , R. A. , Cheson , B. D. and Schiffer , C. A. 2000 . Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia . N. Engl. J. Med. , 343 ( 24 ) : 1750 – 1757 .
   PubMed Web of Science ®Google Scholar
• Rai , K. R. , Peterson , B. L. and Appelbaum , F. R. 2009 . Long-term survival analysis of the North American Intergroup Study C9011 comparing fludarabine (F) and chlorambucil (C) in previously untreated patients with chronic lymphocytic leukemia (CLL) . Blood , abstr 536
   Google Scholar
• Steurer , M. , Pall , G. , Richards , S. , Schwarzer , G. , Bohlius , J. and Greil , R. 2006 . Purine antagonists for chronic lymphocytic leukaemia . Cochrane Database Syst. Rev. , 19 ( 3 ) CD004270
   Google Scholar
• Johnson , S. , Smith , A. G. , Löffler , H. , Osby , E. , Juliusson , G. , Emmerich , B. , Wyld , P. J. and Hiddemann , W. 1996 . Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL . Lancet , 347 : 1432 – 1438 .
   PubMed Web of Science ®Google Scholar
• Robak , T. , Bloński , J. Z. , Kasznicki , M. , Blasińska-Morawiec , M. , Krykowski , E. , Dmoszyńska , A. , Mrugala-Spiewak , H. , Skotnicki , A. B. , Nowak , W. , Konopka , L. , Ceglarek , B. , Maj , S. , Dwilewicz-Trojaczek , J. , Hellmann , A. , Urasiński , I. , Zdziarska , B. , Kotlarek-Haus , S. , Potoczek , S. and Grieb , P. 2000 . Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial . Blood , 96 ( 8 ) : 2723 – 2729 .
   PubMed Web of Science ®Google Scholar
• Hallek , M. 2010 . Therapy of chronic lymphocytic leukaemia . Best Pract. Res. Clin. Haematol. , 23 ( 1 ) : 85 – 96 .
   PubMedGoogle Scholar
• Brogden , R. N. and Sorkin , E. M. 1993 . Pentostatin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in lymphoproliferative disorders . Drugs , 46 ( 4 ) : 652 – 677 .
   PubMed Web of Science ®Google Scholar
• Johnson , S. A. , Catovsky , D. , Child , J. A. , Newland , A. C. , Milligan , D. W. and Janmohamed , R. 1998 . Phase I/II evaluation of pentostatin (2′-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia . Invest. New Drugs , 16 ( 2 ) : 155 – 160 .
   PubMedGoogle Scholar
• Ho , A. D. , Thaler , J. , Stryckmans , P. , Coiffier , B. , Luciani , M. , Sonneveld , P. , Lechner , K. , Rodenhuis , S. , Peetermans , M. E. and deCataldo , F. 1990 . Pentostatin in refractory chronic lymphocytic leukemia: a phase II trial of the European Organization for Research and Treatment of Cancer . J. Natl. Cancer Inst. , 82 ( 17 ) : 1416 – 1420 .
   PubMedGoogle Scholar
• Weiss , M. A. , Maslak , P. G. , Jurcic , J. G. , Scheinberg , D. A. , Aliff , T. B. , Lamanna , N. , Frankel , S. R. , Kossman , S. E. and Horgan , D. 2003 . Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia . J. Clin. Oncol. , 21 ( 7 ) : 1278 – 1284 .
   PubMed Web of Science ®Google Scholar
• Waselenko , J. K. , Grever , M. R. , Beer , M. , Lucas , M. A. and Byrd , J. C. 2000 . Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia . Semin. Oncol. , 27 ( 2 ) : 44 – 51 .
   PubMedGoogle Scholar
• Thursky , K. A. , Worth , L. J. , Seymour , J. F. , Miles Prince , H. and Slavin , M. A. 2006 . Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab* . Br. J. Haematol. , 132 ( 1 ) : 3 – 12 .
   PubMed Web of Science ®Google Scholar
• Eichhorst , B. F. , Busch , R. , Hopfinger , G. , Pasold , R. , Hensel , M. , Steinbrecher , C. , Siehl , S. , Jäger , U. , Bergmann , M. , Stilgenbauer , S. , Schweighofer , C. , Wendtner , C. M. , Döhner , H. , Brittinger , G. , Emmerich , B. and Hallek , M. 2006 . Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia . Blood , 107 ( 3 ) : 885 – 891 .
   PubMed Web of Science ®Google Scholar
• Weiss , M. A. , Glenn , M. , Maslak , P. , Rahman , Z. , Noy , A. , Zelenetz , A. , Scheinberg , D. A. and Golde , D. W. 2000 . Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy . Leukemia , 14 ( 9 ) : 1577 – 1582 .
   PubMedGoogle Scholar
• Laurenti , L. , Tarnani , M. , De Padua , L. , Efremov , D. G. , Zini , G. , Garzia , M. , Piccirillo , N. , Chiusolo , P. , Sorà , F. , Innocenti , I. , Sica , S. and Leone , G. 2008 . Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration . Ann. Hematol. , 87 ( 11 ) : 891 – 898 .
   PubMedGoogle Scholar
• O’Brien , S. M. , Kantarjian , H. M. , Cortes , J. , Beran , M. , Koller , C. A. , Giles , F. J. , Lerner , S. and Keating , M. 2001 . Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia . J. Clin. Oncol. , 19 ( 5 ) : 1414 – 1420 .
   PubMed Web of Science ®Google Scholar
• Hallek , M. , Fischer , K. , Fingerle-Rowson , G. , Fink , A. M. , Busch , R. , Mayer , J. , Hensel , M. , Hopfinger , G. , Hess , G. , von Grünhagen , U. , Bergmann , M. , Catalano , J. , Zinzani , P. L. , Caligaris-Cappio , F. , Seymour , J. F. , Berrebi , A. , Jäger , U. , Cazin , B. , Trneny , M. , Westermann , A. , Wendtner , C. M. , Eichhorst , B. F. , Staib , P. , Bühler , A. , Winkler , D. , Zenz , T. , Böttcher , S. , Ritgen , M. , Mendila , M. , Kneba , M. , Döhner , H. and Stilgenbauer , S. 2010 . Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial . Lancet , 376 ( 9747 ) : 1164 – 1174 .
   PubMed Web of Science ®Google Scholar
• Hillmen , P. 2010 . Chronic lymphocytic leukaemia—moving towards cure? . Lancet , 376 ( 9747 ) : 1122 – 1124 .
   PubMed Web of Science ®Google Scholar
• Molina-Arcas , M. , Marce , S. , Villamor , N. , Huber-Ruano , I. , Casado , F. J. , Bellosillo , B. , Montserrat , E. , Gil , J. , Colomer , D. and Pastor-Anglada , M. 2005 . Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells . Leukemia , 19 ( 1 ) : 64 – 68 .
   PubMedGoogle Scholar
• Marce , S. , Molina-Arcas , M. , Villamor , N. , Casado , F. J. , Campo , E. , Pastor-Anglada , M. and Colomer , D. 2006 . Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma . Haematologica , 91 ( 7 ) : 895 – 902 .
   PubMed Web of Science ®Google Scholar
• Hubeek , I. , Stam , R. W. , Peters , G. J. , Broekhuizen , R. , Meijerink , J. P. , van Wering , E. R. , Gibson , B. E. , Creutzig , U. , Zwaan , C. M. , Cloos , J. , Kuik , D. J. , Pieters , R. and Kaspers , G. J. 2005 . The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia . Br. J. Cancer , 93 ( 12 ) : 1388 – 1394 .
   PubMed Web of Science ®Google Scholar
• Mackey , J. R. , Galmarini , C. M. , Graham , K. A. , Joy , A. A. , Delmer , A. , Dabbagh , L. , Glubrecht , D. , Jewell , L. D. , Lai , R. , Lang , T. , Hanson , J. , Young , J. D. , Merle-Beral , H. , Binet , J. L. , Cass , C. E. and Dumontet , C. 2005 . Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations . Blood , 105 ( 2 ) : 767 – 774 .
   PubMed Web of Science ®Google Scholar
• Tsang , R. , Santos , C. , Ghosh , S. , Dabbagh , L. , King , K. , Young , J. , Cass , C. E. , Mackey , J. R. and Lai , R. 2008 . Immunohistochemistry for human concentrative nucleoside transporter 3 protein predicts fludarabine sensitivity in chronic lymphocytic leukemia . Mod. Pathol. , 21 : 1387 – 1393 .
   PubMed Web of Science ®Google Scholar
• King , K. M. and Cass , C. E. 1994 . Membrane transport of 2- chloro-2′-deoxyadenosine and 2-chloro-2′-arabinofluoro-2′-deoxyadenosine is required for cytotoxicity . Proc. Am. Assoc. Cancer Res , 35 ( A ) : 3436
   Google Scholar
• Hoellein , A. , Decker , T. , Bogner , C. , Oelsner , M. , Hauswald , S. , Peschel , C. , Keller , U. and Licht , T. 2010 . Expression of multidrug resistance-associated ABC transporters in B-CLL is independent of ZAP70 status . J. Cancer Res. Clin. Oncol. , 136 ( 3 ) : 403 – 410 .
   PubMedGoogle Scholar
• Herweijer , H. , Sonneveld , P. , Baas , F. and Nooter , K. 1990 . Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine . J. Natl. Cancer Inst. , 82 ( 13 ) : 1133 – 1140 .
   PubMedGoogle Scholar
• Sonneveld , P. , Nooter , K. , Burghouts , J. T. , Herweijer , H. , Adriaansen , H. J. and van Dongen , J. J. 1992 . High expression of the mdr3 multidrug-resistance gene in advanced-stage chronic lymphocytic leukemia . Blood , 79 ( 6 ) : 1496 – 1500 .
   PubMedGoogle Scholar
• Svirnovski , A. I. , Shman , T. V. , Serhiyenka , T. F. , Savitski , V. P. , Smolnikova , V. V. and Fedasenka , U. U. 2009 . ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells . Hematology Am. Soc. Hematol. Educ. Program , 14 ( 4 ) : 204 – 212 .
   Google Scholar
• Matthews , C. , Catherwood , M. A. , Larkin , A. M. , Clynes , M. , Morris , T. C. and Alexander , H. D. 2006 . MDR-1, but not MDR-3 gene expression, is associated with unmutated IgVH genes and poor prognosis chromosomal aberrations in chronic lymphocytic leukemia . Leuk. Lymphoma , 47 ( 11 ) : 2308 – 2313 .
   PubMed Web of Science ®Google Scholar
• Larkin , A. , Moran , E. , Alexander , D. and Clynes , M. 1999 . Preliminary immunocytochemical studies of MDR-1 and MDR-3 Pgp expression in B-cell leukaemias . Adv. Exp. Med. Biol. , 457 : 65 – 70 .
   PubMed Web of Science ®Google Scholar
• Valdes , R. , Fernandez-Veledo , S. , Aymerich , I. , Casado , F. J. and Pastor-Anglada , M. 2006 . TGF-beta transcriptionally activates the gene encoding the high-affinity adenosine transporter CNT2 in rat liver parenchymal cells . Cell Mol. Life Sci. , 63 ( 21 ) : 2527 – 2537 .
   PubMedGoogle Scholar
• Klein , K. , Kullak-Ublick , G. A. , Wagner , M. , Trauner , M. and Eloranta , J. J. 2009 . Hepatocyte nuclear factor-4alpha and bile acids regulate human concentrative nucleoside transporter-1 gene expression . Am. J. Physiol. Gastrointest. Liver Physiol. , 296 ( 4 ) : G936 – G947 .
   PubMedGoogle Scholar
• Leisewitz , A. V. , Zimmerman , E. I. , Huang , M. , Jones , S. Z. , Yang , J. and Graves , L. M. 2011 . Regulation of ENT1 expression and ENT1-dependent nucleoside transport by c-Jun N-terminal kinase . Biochem. Biophys. Res. Commun. , 404 ( 1 ) : 370 – 375 .
   PubMedGoogle Scholar
• Fernandez Calotti , P. , Galmarini , C. M. , Canones , C. , Gamberale , R. , Saenz , D. , Avalos , J. S. , Chianelli , M. , Rosenstein , R. and Giordano , M. 2008 . Modulation of the human equilibrative nucleoside transporter1 (hENT1) activity by IL-4 and PMA in B cells from chronic lymphocytic leukemia . Biochem. Pharmacol. , 75 ( 4 ) : 857 – 865 .
   PubMedGoogle Scholar
• Coe , I. , Zhang , Y. , McKenzie , T. and Naydenova , Z. 2002 . PKC regulation of the human equilibrative nucleoside transporter, hENT1 . FEBS Lett. , 517 ( 1–3 ) : 201 – 205 .
   PubMedGoogle Scholar
• Fernandez Calotti , P. and Pastor Angada , M. 2010 . All-trans-retinoic acid promotes trafficking of human concentrative nucleoside transporter-3 (hCNT3) to the plasma membrane by a TGF-beta1-mediated mechanism . J. Biol. Chem. , 285 ( 18 ) : 13589 – 13598 .
   PubMedGoogle Scholar